ProCE Banner Activity

MASTERKEY-265: T-VEC + Pembrolizumab Safe, Active in Unresectable Stage IIIB/IV Melanoma

Slideset Download
Conference Coverage
Small phase Ib trial demonstrated that combination treatment with T-VEC plus pembrolizumab in advanced unresectable melanoma yields ORR of 57% and CR of 24%.

Released: June 06, 2016

Expiration: June 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals